EGFR and non-small cell lung carcinoma: EGFR overexpression and activating mutations in NSCLC H3255 cells can promote NSCLC resistance to immunotherapy by upregulating inhibitory immune checkpoints, such as programmed death receptor ligand 1 (PD-L1) and indoleamine-2,3-dioxygenase-1 (IDO1).